Haleon Q3 Earnings: Questions Remain Amid Slow Cough and Cold Season

Haleon's Q3 numbers were in line with expectations, but Barclays analysts say questions still remain. Organic sales growth was 3.4%, with North America OSG at 0.4%. The US sell-out was boosted by restocking, but pricing was below expectations due to a competitive market in Vitamins, Minerals & Supplements. With a potential decline of 1.2% in Q4, Barclays says Haleon is not yet out of the woods and needs to show strong Q4 results to alleviate concerns.